1. Vos T, Flaxman AD, Naghavi M, AlMazroa MA, Memish ZA. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 (vol 380, pg 2163, 2012). Lancet. 2013;381(9867):628.
2. Guidance for industry. Osteoarthritis: structural endpoints for the development of drugs, devices, and biological products for treatment. Rockville: United States Food and Drug Administration; 2018.
3. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr Cartil. 2015;23(8):1233–41.
4. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham study. Am J Public Health. 1994;84(3):351–8.
5. Mankin HJ. Clinical features of osteoarthritis. In: Kelly WN, Harris EDJ, Ruddy S, Sledge CB, editors. Textbook of rheumatology. 4th ed. Philadelphia: W.B. Saunders Co.; 1993. p. 1374–84.